Generated: April 25, 2017
|Title:||Technetium-99m labeled peptides for GPIIb/IIIa ligands useful for thrombus imaging|
|Abstract:||This invention relates to radiolabeled peptides and methods for producing such peptides. Specifically, the invention relates to specific binding peptides, methods and kits for making such peptides, and methods for using such peptides labeled with technetium-99m via a radiolabel-binding moiety covalently linked to the peptide to image thrombus sites in a mammalian body.|
|Inventor(s):||Dean; Richard T. (Bedford, NH), Lister-James; John (Bedford, NH)|
|Assignee:||Diatide, Inc. (Londonderry, NH)|
|Filing Date:||Jun 07, 1995|
|Claims:||1. A reagent for preparing a thrombus imaging agent comprising a specific binding peptide having an amino acid sequence of 4 to 100 amino acids and a technetium-99m binding moiety covalently linked to the peptide, wherein the peptide is selected from the group consisting of a cyclic peptide ligand for a GPIIb/IIIa receptor and a linear peptide ligand for the GPIlb/IIIa receptor not comprising the amino acid sequence (arginine-glycine-aspartate). |
2. A composition comprising a peptide having a formula selected from the group consisting of: ##STR17##
3. The reagent according to claim 1, wherein the peptide and the technetium-99m binding moiety are covalently linked through one or more amino acids.
4. A composition of matter comprising the reagent according to claim 1 and a stannous ion.
5. A kit for preparing a radiopharmaceutical preparation, said kit comprising a sealed vial containing a predetermined quantity of a reagent according to claim 1 and a sufficient amount of a reducing agent to label said reagent with technetium-99m.
6. The reagent according to claim 1, wherein the peptide is chemically synthesized in vitro.
7. The reagent according to claim 6, wherein the peptide is synthesized by solid phase peptide synthesis.
8. The reagent according to claim 6 wherein the technetium-99m binding moiety is covalently linked to the peptide during in vitro chemical synthesis.
9. The reagent according to claim 8 wherein the technetium-99m binding moiety is covalently linked to the peptide during solid phase peptide synthesis.
10. The reagent of claim 1, wherein the peptide is selected from the group consisting of: ##STR18##
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.